Ophthalmology and Optometry Macular Degeneration

Table of Contents

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
Macular Degeneration Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Macular Degeneration Projects
--Allergan Inc
--Alcon Inc
--CoMentis, Inc.
--Bayer Ag
--Intradigm Corporation
--Genentech Inc
--Miravant Medical Technologies
--Merck & Co Inc
--Novartis AG
--Neurotech USA, Inc.
--OXiGENE INC
--Othera Pharmaceuticals, Inc.
--QLT Inc
--Pfizer Inc
--Regeneron Pharmaceuticals Inc
--Quark Pharmaceuticals, Inc.
--Silence Therapeutics plc
--erly SR Pharma plc)
--Sanofi-Aventis
--TargeGen, Inc.
--Sirion Therapeutics, Inc.

--Top Companies in early stage Macular Degeneration Projects
--Alexion Pharmaceuticals Inc
--Advanced Vision Therapies, Inc
--Angstrom Pharmaceuticals, Inc.
--Allergan Inc
--Archemix Corp.
--Antisense Therapeutics Limited
--Cell Genesys Inc
--BioInvent International AB
--Ceregene, Inc
--CellGate, Inc
--Genentech Inc
--ExonHit Therapeutics SA
--GlaxoSmithKline plc
--Genetix Pharmaceuticals, Inc.
--Lpath Inc
--Jerini AG
--Opko Health, Inc.
--Ophthotech Corp.
--Targa Therapeutics Corp.
--Oxford BioMedica plc

Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
--Post Marketing Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View